MovDisordV3, PascalFrancis, Corpus, bibRecord, 000A70

A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy

Identifieur interne : 000A70 ( PascalFrancis/Corpus ); précédent : 000A69; suivant : 000A71

A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy

Auteurs : Anette Schrag ; Shamira Sheikh ; Niall P. Quinn ; Andrew J. Lees ; Caroline Selai ; Chris Mathias ; Irene Litvan ; Anthony E. Lang ; James H. Bower ; David J. Bum ; Philip Low ; Marjan Jahanshahi

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0314988

Descripteurs français

Pascal (Inist)
- Etat dépressif, Angoisse anxiété, Atrophie multisystématisée, Parkinsonisme, Pathologie du système nerveux, Etude comparative, Etat sanitaire, Homme, Ophtalmoplégie supranucléaire, Qualité de vie.

English descriptors

KwdEn :
- Anxiety, Comparative study, Depression, Health status, Human, Multiple system atrophy, Nervous system diseases, Parkinsonism, Quality of life, Supranuclear ophthalmoplegia.

Abstract

The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty-eight patients with PSP and 286 patients with MSA completed EQ-5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self-care was similarly high in both groups after similar duration. Fifty-six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ-5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy`
A11	`01`	`1`		`@1 SCHRAG (Anette)`
A11	`02`	`1`		`@1 SHEIKH (Shamira)`
A11	`03`	`1`		`@1 QUINN (Niall P.)`
A11	`04`	`1`		`@1 LEES (Andrew J.)`
A11	`05`	`1`		`@1 SELAI (Caroline)`
A11	`06`	`1`		`@1 MATHIAS (Chris)`
A11	`07`	`1`		`@1 LITVAN (Irene)`
A11	`08`	`1`		`@1 LANG (Anthony E.)`
A11	`09`	`1`		`@1 BOWER (James H.)`
A11	`10`	`1`		`@1 BUM (David J.)`
A11	`11`	`1`		`@1 LOW (Philip)`
A11	`12`	`1`		`@1 JAHANSHAHI (Marjan)`
A14	`01`			`@1 Institute of Neurology, University College London @2 London @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 12 aut.`
A14	`02`			`@1 Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London @2 London @3 GBR @Z 6 aut.`
A14	`03`			`@1 Movement Disorder Program, Department of Neurology, University of Louisville @2 Louisville, Kentucky @3 USA @Z 7 aut.`
A14	`04`			`@1 Division of Neurology, Toronto Western Hospital and the University of Toronto @2 Toronto, Ontario @3 CAN @Z 8 aut.`
A14	`05`			`@1 Department of Neurology, Mayo Clinic College of Medicine @2 Rochester, Minnesota @3 USA @Z 9 aut.`
A14	`06`			`@1 Institute for Ageing and Health, Newcastle University @2 Newcastle Upon Tyne @3 GBR @Z 10 aut.`
A14	`07`			`@1 Department of Neurology, Mayo Clinic College of Medicine @2 Rochester, Minnesota @3 USA @Z 11 aut.`
A20				`@1 1077-1081`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000170524820160`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 10-0314988`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty-eight patients with PSP and 286 patients with MSA completed EQ-5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self-care was similarly high in both groups after similar duration. Fifty-six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ-5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Etat dépressif @5 01`
C03	`01`	`X`	`ENG`	`@0 Depression @5 01`
C03	`01`	`X`	`SPA`	`@0 Estado depresivo @5 01`
C03	`02`	`X`	`FRE`	`@0 Angoisse anxiété @5 02`
C03	`02`	`X`	`ENG`	`@0 Anxiety @5 02`
C03	`02`	`X`	`SPA`	`@0 Angustia ansiedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Atrophie multisystématisée @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Multiple system atrophy @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Atrofia multisistematizada @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 04`
C03	`04`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 04`
C03	`04`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Etude comparative @5 09`
C03	`06`	`X`	`ENG`	`@0 Comparative study @5 09`
C03	`06`	`X`	`SPA`	`@0 Estudio comparativo @5 09`
C03	`07`	`X`	`FRE`	`@0 Etat sanitaire @5 10`
C03	`07`	`X`	`ENG`	`@0 Health status @5 10`
C03	`07`	`X`	`SPA`	`@0 Estado sanitario @5 10`
C03	`08`	`X`	`FRE`	`@0 Homme @5 11`
C03	`08`	`X`	`ENG`	`@0 Human @5 11`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`09`	`X`	`FRE`	`@0 Ophtalmoplégie supranucléaire @5 12`
C03	`09`	`X`	`ENG`	`@0 Supranuclear ophthalmoplegia @5 12`
C03	`09`	`X`	`SPA`	`@0 Oftalmoplejía supranuclear @5 12`
C03	`10`	`X`	`FRE`	`@0 Qualité de vie @5 13`
C03	`10`	`X`	`ENG`	`@0 Quality of life @5 13`
C03	`10`	`X`	`SPA`	`@0 Calidad vida @5 13`
C07	`01`	`X`	`FRE`	`@0 Trouble de l'humeur @5 37`
C07	`01`	`X`	`ENG`	`@0 Mood disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Trastorno humor @5 37`
C07	`02`	`X`	`FRE`	`@0 Affect affectivité @5 38`
C07	`02`	`X`	`ENG`	`@0 Affect affectivity @5 38`
C07	`02`	`X`	`SPA`	`@0 Afecto afectividad @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Syndrome oculomoteur @5 41`
C07	`05`	`X`	`ENG`	`@0 Oculomotor syndrome @5 41`
C07	`05`	`X`	`SPA`	`@0 Oculomotricidad síndrome @5 41`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'oeil @5 42`
C07	`06`	`X`	`ENG`	`@0 Eye disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Ojo patología @5 42`
C07	`07`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
C07	`08`	`X`	`FRE`	`@0 Syndrome du tronc cérébral @5 45`
C07	`08`	`X`	`ENG`	`@0 Brain stem syndrome @5 45`
C07	`08`	`X`	`SPA`	`@0 Tallo encefalico sindrome @5 45`
N21				`@1 200`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0314988 INIST
ET :	A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy
AU :	SCHRAG (Anette); SHEIKH (Shamira); QUINN (Niall P.); LEES (Andrew J.); SELAI (Caroline); MATHIAS (Chris); LITVAN (Irene); LANG (Anthony E.); BOWER (James H.); BUM (David J.); LOW (Philip); JAHANSHAHI (Marjan)
AF :	Institute of Neurology, University College London/London/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 12 aut.); Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London/London/Royaume-Uni (6 aut.); Movement Disorder Program, Department of Neurology, University of Louisville/Louisville, Kentucky/Etats-Unis (7 aut.); Division of Neurology, Toronto Western Hospital and the University of Toronto/Toronto, Ontario/Canada (8 aut.); Department of Neurology, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (9 aut.); Institute for Ageing and Health, Newcastle University/Newcastle Upon Tyne/Royaume-Uni (10 aut.); Department of Neurology, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (11 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 8; Pp. 1077-1081; Bibl. 25 ref.
LA :	Anglais
EA :	The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty-eight patients with PSP and 286 patients with MSA completed EQ-5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self-care was similarly high in both groups after similar duration. Fifty-six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ-5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP.
CC :	002B17; 002B17F
FD :	Etat dépressif; Angoisse anxiété; Atrophie multisystématisée; Parkinsonisme; Pathologie du système nerveux; Etude comparative; Etat sanitaire; Homme; Ophtalmoplégie supranucléaire; Qualité de vie
FG :	Trouble de l'humeur; Affect affectivité; Pathologie de l'encéphale; Maladie dégénérative; Syndrome oculomoteur; Pathologie de l'oeil; Pathologie du système nerveux central; Syndrome du tronc cérébral
ED :	Depression; Anxiety; Multiple system atrophy; Parkinsonism; Nervous system diseases; Comparative study; Health status; Human; Supranuclear ophthalmoplegia; Quality of life
EG :	Mood disorder; Affect affectivity; Cerebral disorder; Degenerative disease; Oculomotor syndrome; Eye disease; Central nervous system disease; Brain stem syndrome
SD :	Estado depresivo; Angustia ansiedad; Atrofia multisistematizada; Parkinson síndrome; Sistema nervioso patología; Estudio comparativo; Estado sanitario; Hombre; Oftalmoplejía supranuclear; Calidad vida
LO :	INIST-20953.354000170524820160
ID :	10-0314988

Links to Exploration step

Pascal:10-0314988

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sheikh, Shamira" sort="Sheikh, Shamira" uniqKey="Sheikh S" first="Shamira" last="Sheikh">Shamira Sheikh</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name>
<affiliation><inist:fA14 i1="03"><s1>Movement Disorder Program, Department of Neurology, University of Louisville</s1>
<s2>Louisville, Kentucky</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Toronto Western Hospital and the University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bum, David J" sort="Bum, David J" uniqKey="Bum D" first="David J." last="Bum">David J. Bum</name>
<affiliation><inist:fA14 i1="06"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Low, Philip" sort="Low, Philip" uniqKey="Low P" first="Philip" last="Low">Philip Low</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jahanshahi, Marjan" sort="Jahanshahi, Marjan" uniqKey="Jahanshahi M" first="Marjan" last="Jahanshahi">Marjan Jahanshahi</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0314988</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0314988 INIST</idno>
<idno type="RBID">Pascal:10-0314988</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A70</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy</title>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sheikh, Shamira" sort="Sheikh, Shamira" uniqKey="Sheikh S" first="Shamira" last="Sheikh">Shamira Sheikh</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Quinn, Niall P" sort="Quinn, Niall P" uniqKey="Quinn N" first="Niall P." last="Quinn">Niall P. Quinn</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mathias, Chris" sort="Mathias, Chris" uniqKey="Mathias C" first="Chris" last="Mathias">Chris Mathias</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Litvan, Irene" sort="Litvan, Irene" uniqKey="Litvan I" first="Irene" last="Litvan">Irene Litvan</name>
<affiliation><inist:fA14 i1="03"><s1>Movement Disorder Program, Department of Neurology, University of Louisville</s1>
<s2>Louisville, Kentucky</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, Toronto Western Hospital and the University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bower, James H" sort="Bower, James H" uniqKey="Bower J" first="James H." last="Bower">James H. Bower</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bum, David J" sort="Bum, David J" uniqKey="Bum D" first="David J." last="Bum">David J. Bum</name>
<affiliation><inist:fA14 i1="06"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Low, Philip" sort="Low, Philip" uniqKey="Low P" first="Philip" last="Low">Philip Low</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jahanshahi, Marjan" sort="Jahanshahi, Marjan" uniqKey="Jahanshahi M" first="Marjan" last="Jahanshahi">Marjan Jahanshahi</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anxiety</term>
<term>Comparative study</term>
<term>Depression</term>
<term>Health status</term>
<term>Human</term>
<term>Multiple system atrophy</term>
<term>Nervous system diseases</term>
<term>Parkinsonism</term>
<term>Quality of life</term>
<term>Supranuclear ophthalmoplegia</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Etat dépressif</term>
<term>Angoisse anxiété</term>
<term>Atrophie multisystématisée</term>
<term>Parkinsonisme</term>
<term>Pathologie du   système nerveux</term>
<term>Etude comparative</term>
<term>Etat sanitaire</term>
<term>Homme</term>
<term>Ophtalmoplégie supranucléaire</term>
<term>Qualité de vie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty-eight patients with PSP and 286 patients with MSA completed EQ-5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self-care was similarly high in both groups after similar duration. Fifty-six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ-5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHRAG (Anette)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SHEIKH (Shamira)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>QUINN (Niall P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LEES (Andrew J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SELAI (Caroline)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MATHIAS (Chris)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LITVAN (Irene)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BOWER (James H.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>BUM (David J.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>LOW (Philip)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>JAHANSHAHI (Marjan)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Movement Disorder Program, Department of Neurology, University of Louisville</s1>
<s2>Louisville, Kentucky</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Neurology, Toronto Western Hospital and the University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Mayo Clinic College of Medicine</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>1077-1081</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000170524820160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0314988</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty-eight patients with PSP and 286 patients with MSA completed EQ-5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self-care was similarly high in both groups after similar duration. Fifty-six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ-5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Depression</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Angoisse anxiété</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Anxiety</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Angustia ansiedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Atrophie multisystématisée</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Multiple system atrophy</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Atrofia multisistematizada</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Etat sanitaire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Health status</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Estado sanitario</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Ophtalmoplégie supranucléaire</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Supranuclear ophthalmoplegia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Oftalmoplejía supranuclear</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Qualité de vie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Quality of life</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Calidad vida</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble de l'humeur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Affect affectivité</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Affect affectivity</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Afecto afectividad</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Syndrome oculomoteur</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Oculomotor syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Oculomotricidad síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'oeil</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Syndrome du tronc cérébral</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Brain stem syndrome</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Tallo encefalico sindrome</s0>
<s5>45</s5>
</fC07>
<fN21><s1>200</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0314988 INIST</NO>
<ET>A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy</ET>
<AU>SCHRAG (Anette); SHEIKH (Shamira); QUINN (Niall P.); LEES (Andrew J.); SELAI (Caroline); MATHIAS (Chris); LITVAN (Irene); LANG (Anthony E.); BOWER (James H.); BUM (David J.); LOW (Philip); JAHANSHAHI (Marjan)</AU>
<AF>Institute of Neurology, University College London/London/Royaume-Uni (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 12 aut.); Neurovascular Medicine Unit, Faculty of Medicine, Imperial College London/London/Royaume-Uni (6 aut.); Movement Disorder Program, Department of Neurology, University of Louisville/Louisville, Kentucky/Etats-Unis (7 aut.); Division of Neurology, Toronto Western Hospital and the University of Toronto/Toronto, Ontario/Canada (8 aut.); Department of Neurology, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (9 aut.); Institute for Ageing and Health, Newcastle University/Newcastle Upon Tyne/Royaume-Uni (10 aut.); Department of Neurology, Mayo Clinic College of Medicine/Rochester, Minnesota/Etats-Unis (11 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 8; Pp. 1077-1081; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>The objective of this study was to compare subjective health status and its correlates in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). One hundred eighty-eight patients with PSP and 286 patients with MSA completed EQ-5D and Hospital Depression and Anxiety Scale. The impact on mobility, usual activities, and self-care was similarly high in both groups after similar duration. Fifty-six percent of PSP and 43% of MSA had probable depression, and 37% of both groups had probable anxiety. Patients with PSP had significantly higher depression scores, but groups did not differ in anxiety scores. Patients with MSA had significantly greater pain/discomfort than patients with PSP. The most important association with subjective health status was with depressive symptoms, which accounted for 38% and 29% of EQ-5D variance in patients with PSP and MSA, followed by disease severity and anxiety scores. We conclude that depressive symptoms were common in both disorders, but more severe in PSP. Anxiety symptoms affected 37% of patients in both groups and contributed to impaired subjective health status. Pain was more problematic in MSA than PSP.</EA>
<CC>002B17; 002B17F</CC>
<FD>Etat dépressif; Angoisse anxiété; Atrophie multisystématisée; Parkinsonisme; Pathologie du système nerveux; Etude comparative; Etat sanitaire; Homme; Ophtalmoplégie supranucléaire; Qualité de vie</FD>
<FG>Trouble de l'humeur; Affect affectivité; Pathologie de l'encéphale; Maladie dégénérative; Syndrome oculomoteur; Pathologie de l'oeil; Pathologie du   système nerveux central; Syndrome du tronc cérébral</FG>
<ED>Depression; Anxiety; Multiple system atrophy; Parkinsonism; Nervous system diseases; Comparative study; Health status; Human; Supranuclear ophthalmoplegia; Quality of life</ED>
<EG>Mood disorder; Affect affectivity; Cerebral disorder; Degenerative disease; Oculomotor syndrome; Eye disease; Central nervous system disease; Brain stem syndrome</EG>
<SD>Estado depresivo; Angustia ansiedad; Atrofia multisistematizada; Parkinson síndrome; Sistema nervioso patología; Estudio comparativo; Estado sanitario; Hombre; Oftalmoplejía supranuclear; Calidad vida</SD>
<LO>INIST-20953.354000170524820160</LO>
<ID>10-0314988</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A70 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000A70 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0314988
   |texte=   A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy

A Comparison of Depression, Anxiety, and Health Status in Patients with Progressive Supranuclear Palsy and Multiple System Atrophy

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri